AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX 11,896
+46 (0.39%)
Aug 7, 2026, 5:15 PM GMT
AstraZeneca Revenue
AstraZeneca had revenue of $15.38B USD in the quarter ending June 30, 2026, with 6.41% growth. This brings the company's revenue in the last twelve months to $61.37B, up 8.61% year-over-year. In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth.
Revenue (ttm)
$61.37B
Revenue Growth
+8.61%
P/S Ratio
3.99
Revenue / Employee
$638.56K
Employees
96,100
Market Cap
184.51B GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.74B | 4.67B | 8.63% |
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 33.20B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| Hikma Pharmaceuticals | 2.58B |
| Convatec Group | 1.88B |
| Spire Healthcare Group | 1.58B |
| CVS Group | 692.80M |
| Genus | 672.00M |
AstraZeneca News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PRNewsWire
- 2 days ago - AstraZeneca (AZN) Explores Merger Talks with Bristol-Myers Squibb - GuruFocus
- 2 days ago - AstraZeneca may buck a decade of pharma strategy to buy U.S. scale - CNBC
- 2 days ago - Deal or No Deal, AstraZeneca Stock Is a Bargain - WSJ
- 3 days ago - AstraZeneca PLC (AZN) Stock Up 3.8% and Still Undervalued -- GF Score: 83/100 - GuruFocus
- 3 days ago - AstraZeneca shares rise as fresh reports deny mega-merger talks with US rival - This is Money
- 3 days ago - Soriot should explain the curious case of AstraZeneca’s non-deal - The Guardian
- 3 days ago - No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal - TipRanks